摘要
目的:研究甲氨蝶呤联合ICE方案(异环磷酰胺、依托泊苷、卡铂)治疗弥漫大B细胞淋巴瘤(DLBCL)的疗效及生存情况。方法:选取2020年9月至2021年9月于我院治疗的110例DLBCL患者作为研究对象,实施回顾性分析,根据治疗方式的不同分为观察组(66例,甲氨蝶呤联合ICE方案治疗)和对照组(44例,ICE方案治疗)。比较两组患者临床疗效、生化指标、并发症发生情况和生存情况。结果:观察组患者肿瘤控制率高于对照组(P<0.05)。治疗后,观察组患者血管内皮生长因子(VEGF)、β2微球蛋白(β2-MG)、乳酸脱氢酶(LDH)、糖类抗原125(CA125)水平均低于对照组,且以上各指标均呈正相关关系(P<0.05)。两组患者并发症种类数差异无统计学意义(P>0.05)。观察组患者生存期大于9个月的比例高于对照组(P<0.05)。影响患者生存期的因素有分组(治疗方法)、骨髓侵犯、国际预后指数(IPI指数)、年龄、体质量指数(BMI)、病灶数、VEGF。结论:甲氨蝶呤联合ICE方案治疗DLBCL有效,可改善患者临床癌症指标,延长患者生存期。
Objective:To study the efficacy and survival of methotrexate combined with ICE regimen(ifosfamide,etoposide,carboplatin)in the treatment of diffuse large B-cell lymphoma(DLBCL).Methods:110 DLBCL patients admitted in our hospital from September 2020 to September 2021were selected as the research objects for retrospective analysis,and were divided into the observation group(66 cases,methotrexate combined ICE regimen treatment)and the control group(44 cases,ICE regimen treatment)according to different treatment methods.The clinical efficacy,biochemical indexes,complications and survival of the two groups of patients were compared.Results:The tumor control rate of the observation group was higher than that of the control group(P<0.05).After treatment,the levels of VEGF,β2-MG,LDH and CA125 of patients in the observation group were lower than those in the control group,and there was a positive correlation between the above indicators(P<0.05).There was no statistical difference in the number of complications between the two groups(P>0.05).The proportion of patients with survival longer than 9 months in the observation group was higher than that of the controlgroup(P<0.05).The factors influencing the survival of patients were grouping(treatment method),bone marrow invasion,IPI index,age,BMI,number of lesions and VEGF.Conclusion:Methotrexate combined with ICE regimen is effective in the treatment of DLBCL,which can improve the clinical cancer indicators and prolong the survival of patients.
作者
李新涛
申兴勇
刘爽
刘逸之
LI Xintao;SHEN Xingyong;LIU Shuang;LIU Yizhi(Department of Internal Medicine,Shaanxi Provincial Cancer Hospital,Shaanxi Xi′an 710061,China;Department of Hematology and Oncology,Xi′an People′s Hospital(Xi′an Fourth Hospital),Shaanxi Xi′an 710004,China)
出处
《中国医药导刊》
2022年第12期1204-1210,共7页
Chinese Journal of Medicinal Guide
作者简介
李新涛,男,硕士,主治医师,研究方向:肺癌、乳腺癌等恶性肿瘤的综合治疗。E-mail:lxt71688@163.com;通讯作者:刘逸之,男,副主任医师,研究方向:恶性肿瘤/内科治疗。E-mail:lyz-zt@163.com。
